Publications 2021

Aamodt AH, Høgestøl EA, Popperud TH, Holter JC, Dyrhol-Riise AM, Tonby K, Stiksrud B, Quist-Paulsen E, Berge T, Barratt-Due A, Aukrust P, Heggelund L, Blennow K, Zetterberg H, Harbo HF (2021)
Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19
J Neurol, 268 (10), 3574-3583
DOI 10.1007/s00415-021-10517-6, PubMed 33743046

Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Kildal AB, Berg Å, Johannessen A, Heggelund L, Dahl TB, Skåra KH, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR, Olsen RB et al. (2021)
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial
Ann Intern Med, 174 (9), 1261-1269
DOI 10.7326/M21-0653, PubMed 34251903

Chendi BH, Snyders CI, Tonby K, Jenum S, Kidd M, Walzl G, Chegou NN, Dyrhol-Riise AM (2021)
A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries
Front Immunol, 12, 608846
DOI 10.3389/fimmu.2021.608846, PubMed 33732236

Chendi BH, Tveiten H, Snyders CI, Tonby K, Jenum S, Nielsen SD, Hove-Skovsgaard M, Walzl G, Chegou NN, Dyrhol-Riise AM (2021)
CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries
J Infect, 83 (4), 433-443
DOI 10.1016/j.jinf.2021.07.036, PubMed 34333033

Christensen EE, Jørgensen MJ, Nore KG, Dahl TB, Yang K, Ranheim T, Huse C, Lind A, Nur S, Stiksrud B, Jenum S, Tonby K, Holter JC, Holten AR, Halvorsen B, Dyrhol-Riise AM (2021)
Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns
J Intern Med, 290 (3), 677-692
DOI 10.1111/joim.13310, PubMed 34080738

Jenum S, Tonby K, Rueegg CS, Rühwald M, Kristiansen MP, Bang P, Olsen IC, Sellæg K, Røstad K, Mustafa T, Taskén K, Kvale D, Mortensen R, Dyrhol-Riise AM (2021)
A Phase I/II randomized trial of H56:IC31 vaccination and adjunctive cyclooxygenase-2-inhibitor treatment in tuberculosis patients
Nat Commun, 12 (1), 6774
DOI 10.1038/s41467-021-27029-6, PubMed 34811370

Jøntvedt Jørgensen M, Nore KG, Aass HCD, Layre E, Nigou J, Mortensen R, Tasken K, Kvale D, Jenum S, Tonby K, Dyrhol-Riise AM (2021)
Plasma LOX-Products and Monocyte Signaling Is Reduced by Adjunctive Cyclooxygenase-2 Inhibitor in a Phase I Clinical Trial of Tuberculosis Patients
Front Cell Infect Microbiol, 11, 669623
DOI 10.3389/fcimb.2021.669623, PubMed 34307194

Kåsine T, Dyrhol-Riise AM, Barratt-Due A, Kildal AB, Olsen IC, Nezvalova-Henriksen K, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, Eiken R, Berg Å, Johannessen A, Heggelund L, Dahl TB, Halvorsen B, Mielnik P, Le LAK, Thoresen L, Ernst G, Hoff DAL, Skudal H, Kittang BR et al. (2021)
Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial
J Intern Med
DOI 10.1111/joim.13377, PubMed 34411368

Kolberg ES, Wickstrøm K, Tonby K, Dyrhol-Riise AM, Holten AR, Amundsen EK (2021)
Serum ACE as a prognostic biomarker in COVID-19: a case series
APMIS, 129 (4), 237-238
DOI 10.1111/apm.13108, PubMed 33368687

Lerum TV, Aaløkken TM, Brønstad E, Aarli B, Ikdahl E, Lund KMA, Durheim MT, Rodriguez JR, Meltzer C, Tonby K, Stavem K, Skjønsberg OH, Ashraf H, Einvik G (2021)
Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19
Eur Respir J, 57 (4)
DOI 10.1183/13993003.03448-2020, PubMed 33303540

Watne LO, Tonby K, Holten AR, Olasveengen TM, Romundstad LG, Neerland BE (2021)
Delirium is common in patients hospitalized with COVID-19
Intern Emerg Med, 16 (7), 1997-2000
DOI 10.1007/s11739-021-02715-x, PubMed 33830418

Wickstrøm KE, Vitelli V, Carr E, Holten AR, Bendayan R, Reiner AH, Bean D, Searle T, Shek A, Kraljevic Z, Teo J, Dobson R, Tonby K, Köhn-Luque A, Amundsen EK (2021)
Regional performance variation in external validation of four prediction models for severity of COVID-19 at hospital admission: An observational multi-centre cohort study
PLoS One, 16 (8), e0255748
DOI 10.1371/journal.pone.0255748, PubMed 34432797

Publications 2020

Borén HK, Thaulow CM, Quist-Paulsen E, Wæhre T, Akselsen PE, Tonby K (2020)
Antibiotic use in hospitals in cases of COVID-19
Tidsskr Nor Laegeforen, 140 (11)
DOI 10.4045/tidsskr.20.0443, PubMed 32815355

Gundem T, Olasveengen TM, Hovda KE, Gaustad K, Schøndorf C, Rostrup M, Frøyshov S, Undseth Ø, Tonby K, Holten AR, Sunde K (2020)
T.M. Gundem and colleagues respond
Tidsskr Nor Laegeforen, 140 (12)
DOI 10.4045/tidsskr.20.0650, PubMed 32900164

Gundem T, Olasveengen TM, Hovda KE, Gaustad K, Schøndorf C, Rostrup M, Frøyshov S, Undseth Ø, Tonby K, Holten AR, Sunde K (2020)
Ventilatory support for hypoxaemic intensive care patients with COVID-19
Tidsskr Nor Laegeforen, 140 (11)
DOI 10.4045/tidsskr.20.0445, PubMed 32815344

Holten AR, Nore KG, Tveiten CEVWK, Olasveengen TM, Tonby K (2020)
Predicting severe COVID-19 in the Emergency Department
Resusc Plus, 4, 100042
DOI 10.1016/j.resplu.2020.100042, PubMed 33403367

Holter JC, Pischke SE, de Boer E, Lind A, Jenum S, Holten AR, Tonby K, Barratt-Due A, Sokolova M, Schjalm C, Chaban V, Kolderup A, Tran T, Tollefsrud Gjølberg T, Skeie LG, Hesstvedt L, Ormåsen V, Fevang B, Austad C, Müller KE, Fladeby C, Holberg-Petersen M, Halvorsen B, Müller F, Aukrust P et al. (2020)
Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
Proc Natl Acad Sci U S A, 117 (40), 25018-25025
DOI 10.1073/pnas.2010540117, PubMed 32943538

Jøntvedt Jørgensen M, Holter JC, Christensen EE, Schjalm C, Tonby K, Pischke SE, Jenum S, Skeie LG, Nur S, Lind A, Opsand H, Enersen TB, Grøndahl R, Hermann A, Dudman S, Muller F, Ueland T, Mollnes TE, Aukrust P, Heggelund L, Holten AR, Dyrhol-Riise AM (2020)
Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19
Sci Rep, 10 (1), 21697
DOI 10.1038/s41598-020-78710-7, PubMed 33303843

Jøntvedt Jørgensen M, Jenum S, Tonby K, Mortensen R, Walzl G, Du Plessis N, Dyrhol-Riise AM (2020)
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors
J Leukoc Biol, 110 (1), 177-186
DOI 10.1002/JLB.4A0720-409RR, PubMed 33155730

Nore KG, Jørgensen MJ, Dyrhol-Riise AM, Jenum S, Tonby K (2020)
Elevated Levels of Anti-Inflammatory Eicosanoids and Monocyte Heterogeneity in Mycobacterium tuberculosis Infection and Disease
Front Immunol, 11, 579849
DOI 10.3389/fimmu.2020.579849, PubMed 33304347

Ueland T, Heggelund L, Lind A, Holten AR, Tonby K, Michelsen AE, Jenum S, Jørgensen MJ, Barratt-Due A, Skeie LG, Nordøy I, Aanensen Fraz MS, Quist-Paulsen E E, Pischke SE, Johal SK, Hesstvedt L, Bogen M, Fevang B, Halvorsen B, Müller F, Bekken GK, Mollnes TE, Dudman S, Aukrust P, Dyrhol-Riise AM et al. (2020)
Elevated plasma sTIM-3 levels in patients with severe COVID-19
J Allergy Clin Immunol, 147 (1), 92-98
DOI 10.1016/j.jaci.2020.09.007, PubMed 32971109

Publications 2019

Mortensen R, Clemmensen HS, Woodworth JS, Therkelsen ML, Mustafa T, Tonby K, Jenum S, Agger EM, Dyrhol-Riise AM, Andersen P (2019)
Cyclooxygenase inhibitors impair CD4 T cell immunity and exacerbate Mycobacterium tuberculosis infection in aerosol-challenged mice
Commun Biol, 2, 288
DOI 10.1038/s42003-019-0530-3, PubMed 31396568

Tonby K, Mortensen R, Ruhwald M, Dyrhol-Riise AM, Jenum S (2019)
KLRG1-Expressing CD4 T Cells Are Reduced in Tuberculosis Patients Compared to Healthy Mycobacterium tuberculosis-Infected Subjects, but Increase With Treatment
J Infect Dis, 220 (1), 174-176
DOI 10.1093/infdis/jiz056, PubMed 30888024

Publications 2016

Tonby K, Wergeland I, Lieske NV, Kvale D, Tasken K, Dyrhol-Riise AM (2016)
The COX- inhibitor indomethacin reduces Th1 effector and T regulatory cells in vitro in Mycobacterium tuberculosis infection
BMC Infect Dis, 16 (1), 599
DOI 10.1186/s12879-016-1938-8, PubMed 27776487

Publications 2015

Feruglio SL, Tonby K, Kvale D, Dyrhol-Riise AM (2015)
Early dynamics of T helper cell cytokines and T regulatory cells in response to treatment of active Mycobacterium tuberculosis infection
Clin Exp Immunol, 179 (3), 454-65
DOI 10.1111/cei.12468, PubMed 25313008

Lieske NV, Tonby K, Kvale D, Dyrhol-Riise AM, Tasken K (2015)
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors
PLoS One, 10 (11), e0141903
DOI 10.1371/journal.pone.0141903, PubMed 26544592

Tonby K, Ruhwald M, Kvale D, Dyrhol-Riise AM (2015)
IP-10 measured by Dry Plasma Spots as biomarker for therapy responses in Mycobacterium Tuberculosis infection
Sci Rep, 5, 9223
DOI 10.1038/srep09223, PubMed 25783975

Wergeland I, Pullar N, Assmus J, Ueland T, Tonby K, Feruglio S, Kvale D, Damås JK, Aukrust P, Mollnes TE, Dyrhol-Riise AM (2015)
IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy
J Infect, 70 (4), 381-91
DOI 10.1016/j.jinf.2014.12.019, PubMed 25597826

Publications 2014

Pullar ND, Steinum H, Tonby K, Heggelund L, Leiva RA, Ofstad R, Bruun JN, Dyrhol-Riise AM (2014)
Low prevalence of positive interferon-gamma tests in HIV-positive long-term immigrants in Norway
Int J Tuberc Lung Dis, 18 (2), 180-7
DOI 10.5588/ijtld.13.0276, PubMed 24429310